Donanemab

Safety Profile of Donanemab

Known Side Effects:
Evidence indicates that donanemab can lead to some adverse effects. In particular, a case report in Cureus (2026) described recurrent seizures in a patient with Alzheimer's disease and epilepsy who was treated with donanemab, even in the absence of amyloid-related imaging abnormalities (ARIA). This suggests that seizures may be a potential side effect, especially in individuals with a history of epilepsy.

Contraindications:
While specifics on contraindications are not provided in the sources, the instance of seizures implies that caution should be used in individuals with a history of epilepsy or seizure disorders. Additionally, as with many treatments targeting amyloid in Alzheimer's, those with severe allergic reactions to similar medications might also be contraindicated.

Drug Interactions:
The provided evidence does not offer detailed insights into specific drug interactions with donanemab. As a conservative approach, patients should discuss the use of donanemab with their healthcare provider to consider potential interactions with other Alzheimer's medications or treatments.

Populations to Avoid:
There is a lack of specific evidence on populations that should entirely avoid donanemab. However, the mention of seizures suggests that individuals with a history of epilepsy may need to be particularly cautious. More data from clinical studies would be needed to draw robust conclusions on other populations that should avoid this therapy.

Evidence Limitations:
The current evidence on the safety profile of donanemab, particularly regarding contraindications and drug interactions, is limited. Researchers and clinicians should continue to monitor and report on the safety outcomes of this medication as more data becomes available from ongoing and future clinical trials.

Disclaimer:
This information is not intended as personalized medical advice. Please consult a healthcare provider for advice tailored to individual health conditions.